Prostaglandin E\(_2\) Produced by the Lung Augments the Effector Phase of Allergic Inflammation

Rachel J. Church, Leigh A. Jania and Beverly H. Koller

*J Immunol* 2012; 188:4093-4102; Prepublished online 12 March 2012; doi: 10.4049/jimmunol.1101873

http://www.jimmunol.org/content/188/8/4093

---

**Supplementary Material**

http://www.jimmunol.org/content/suppl/2012/03/13/jimmunol.1101873.DC1

**References**

This article cites 76 articles, 34 of which you can access for free at: http://www.jimmunol.org/content/188/8/4093.full#ref-list-1

**Subscription**

Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

**Permissions**

Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**

Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Prostaglandin E\textsubscript{2} Produced by the Lung Augments the Effector Phase of Allergic Inflammation

Rachel J. Church,\textsuperscript{*} Leigh A. Jania,\textsuperscript{†} and Beverly H. Koller\textsuperscript{*\textdagger};\textsuperscript{*,†}

Elevated PGE\textsubscript{2} is a hallmark of most inflammatory lesions. This lipid mediator can induce the cardinal signs of inflammation, and the beneficial actions of nonsteroidal anti-inflammatory drugs are attributed to inhibition of cyclooxygenase (COX)-1 and COX-2, enzymes essential in the biosynthesis of PGE\textsubscript{2} from arachidonic acid. However, both clinical studies and rodent models suggest that, in the asthmatic lung, PGE\textsubscript{2} acts to restrain the immune response and limit physiological change secondary to inflammation. To directly address the role of PGE\textsubscript{2} in the lung, we examined the development of disease in mice lacking microsomal PGE\textsubscript{2} synthase-1 (mPGES1), which converts COX-1/COX-2-derived PGH\textsubscript{2} to PGE\textsubscript{2}. We show that mPGES1 determines PGE\textsubscript{2} levels in the naive lung and is required for increases in PGE\textsubscript{2} after OVA-induced allergy. Although loss of either COX-1 or COX-2 increases the disease severity, surprisingly, mPGES1\textsuperscript{--/-} mice show reduced inflammation. However, an increase in serum IgE is still observed in the mPGES1\textsuperscript{--/-} mice, suggesting that loss of PGE\textsubscript{2} does not impair induction of a Th2 response. Furthermore, mPGES1\textsuperscript{--/-} mice expressing a transgenic OVA-specific TCR are also protected, indicating that PGE\textsubscript{2} acts primarily after challenge with inhaled Ag. PGE\textsubscript{2} produced by the lung plays the critical role in this response, as loss of lung mPGES1 is sufficient to protect against disease. Together, this supports a model in which mPGES1-dependent PGE\textsubscript{2} produced by populations of cells native to the lung contributes to the effector phase of some allergic responses. The Journal of Immunology, 2012, 188: 4093–4102.
(WT) animals (23). Consistent with this, treatment of mice with indomethacin, a nonsteroidal anti-inflammatory drug (NSAID) that suppresses the actions of both COX-1 and COX-2, or alternatively, with COX-specific NSAIDs, induced elevated eosinophilia and IL-13 production in the lung (24, 25), although these approaches did not allow for the identification of the specific PG (s) responsible for limiting the allergic response. Another study, however, reported increased allergic inflammation in mice lacking EP3 receptors (26), suggesting that loss of PGE2 is at least partly responsible for heightened inflammation observed in COX-deficient and NSAID-treated animals.

PGE2 production occurs through the metabolism of PGH2 by the microsomal PGE2 synthase-1 (mPGES1) (5). Although initially two additional enzymes, cytosolic PGE2 synthase and microsomal PGE2 synthase-2 (mPGES2), were thought to be capable of this enzymatic conversion, studies using mutant mouse lines carrying mutations in the genes for synthases mPges1, cPges/p23, or mPges2, respectively, have failed to support this in vivo function for any product other than mPGES1 (27–29). mPGES1 is expressed in many tissues and cell types of both humans and animals, including in the lung and leukocytes (5, 30, 31). Similar to COX-2, the expression of mPGES1 increases dramatically in response to inflammatory mediators, suggesting coupling with this enzyme; however, evidence demonstrates that mPGES1 can couple with both COX-1 and COX-2 to synthesize PGE2 (5, 29, 30, 32). Furthermore, studies using mice lacking mPGES1 in models of pain nociception, rheumatoid arthritis, atherogenesis, and abdominal aortic aneurysm provide evidence that this synthase contributes to the pathogenesis of both acute and chronic inflammation (29, 33–35).

In this study, we elucidate the contribution of mPGES1-derived PGE2 in the development of allergic lung disease, a mouse model of asthma. First, using congenic mouse lines lacking either COX-1 or COX-2, we confirm the role of this pathway in our model. We then evaluate the role of PGE2 produced by mPGES1 expressed by resident airway cells and PGE2 released from recruited inflammatory cells in this allergic response.

Materials and Methods

Experimental animals

All experiments were conducted in accordance with standard guidelines as defined by the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee guidelines of the University of North Carolina at Chapel Hill. Experiments were carried out on age- and sex-matched mice between 8 and 12 wk of age. C57BL/6 (B6) (backcrossed 120 generations) COX-1−/−, B6 × 129S6/SvEv (129) filial generation (F1) COX-2−/−, and B6 (backcrossed >10 generations) mPGES1−/− mice were generated as described previously (29, 36, 37). B6 OVA-specific TCR-transgenic (OT-II) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). OT-II mice were crossed to mPGES1−/− mice to generate OT-II/mPGES1−/− animals.

OVA sensitization and challenge

All mice were sensitized systemically on days 0 and 14 with an i.p injection of 40 μg OVA (Sigma-Aldrich) emulsified in aluminum hydroxide (alum; Sigma-Aldrich). One week following the second injection, experimental mice were challenged for 5 consecutive d (days 21–25) with an aerosol instillation of 1% OVA in 0.9% NaCl for 1 h each day. Control animals were challenged with 0.9% NaCl only. Twenty-four hours after the final challenge, lung mechanics were measured, and bronchoalveolar lavage fluid (BALF), serum, whole lungs, and spleens were collected for further analysis. For experiments examining allergic sensitization, animals were immunized as described and harvested on day 21.

Measurement of cell proliferation

Splenocytes were prepared by mechanical dispersion of spleen over a 70-μm cell strainer (BD Falcon). RBCs were lysed in lysis buffer (4.1 g NH4Cl, 0.5 g KHCO3, and 100 μL 0.5M EDTA dissolved in 500 mL distilled H2O), and splenocytes were washed twice in PBS. Cells were plated at a density of 2.5 × 106 cells/ml in RPMI 1640 media enriched with 10% FBS, 100 U/ml penicillin, 100 U/ml streptomycin, and 0.29 μg/ml L-glutamine. OVA was added to splenocyte cultures at concentrations ranging from 0–100 μg/ml. After incubation for 72 h at 37˚C, cell proliferation was assessed using WST-1 reagent (Roche) according to the manufacturer’s instructions.

Measurement of airway mechanics in intubated mice

Mechanical ventilation and airway mechanic measurements were conducted as previously described (36). Briefly, mice were anesthetized with 70–90 mg/kg pentobarbital sodium (American Pharmaceutical Partners, Los Angeles, CA), tracheostomized, and mechanically ventilated with a computer-controlled small-animal ventilator. Once ventilated, mice were paralyzed with 0.8 mg/kg pancuronium bromide. Forced oscillatory mechanics were measured every 10 s for 3 min. These measurements allowed for the assessment of airway resistance in the central airways as well as in tissue damping. Increasing doses (between 0 and 50 mg/ml) of methacholine chloride (Mch) were administered to animals through a nebulizer to measure AHR. These data are presented as percent above baseline.

BALF collection and cell counts

Measurements of lung mechanics, mice were anesthetized with 70–90 mg/kg pentobarbital sodium (American Pharmaceutical Partners, Los Angeles, CA), tracheostomized, and mechanically ventilated with a computer-controlled small-animal ventilator. Once ventilated, mice were paralyzed with 0.8 mg/kg pancuronium bromide. Forced oscillatory mechanics were measured every 10 s for 3 min. These measurements allowed for the assessment of airway resistance in the central airways as well as in tissue damping. Increasing doses (between 0 and 50 mg/ml) of methacholine chloride (Mch) were administered to animals through a nebulizer to measure AHR. These data are presented as percent above baseline.

PGE2 and cytokine production

Levels of cytokines and PGE2 were determined by immunoassay in BALF, lung tissue homogenate, and/or tissue culture supernatant. To determine cytokine production by stimulated splenocytes, cells were prepared as described above. Cells were cultured at a density of 1 × 106 cells/ml in the presence of 100 μg/ml OVA. After 72 h, supernatants were collected and stored at −80˚C prior to evaluation by ELISA. To determine lung cytokine and PGE2 levels, lungs were flash frozen in liquid nitrogen, weighed, and stored at −80˚C. Lung tissue was pulverized and homogenized in buffer containing 150 mM NaCl, 15 mM Tris-HCl, 1 mM CaCl2, and 1 mM MgCl2 supplemented with protease inhibitor (Roche). Values shown represent the total quantity of cytokine or mediator measured divided by tissue weight. Cytokines were determined by ELISA following manufacturer’s protocols: IL-13 (R&D Systems), IFN-γ (R&D Systems), IL-4 (R&D Systems), IL-17a (eBioscience). For quantification of PGE2, lung tissue was pulv

Bone marrow chimera generation

Recipient mice were exposed to 5 grays irradiation from a Cesium γ-iradiator at 0 and 3 h. Femurs and tibias were collected from donor mice and flushed with cold PBS to isolate bone marrow. Bone marrow was obtained by cardiac puncture, allowed to coagulate, and centrifuged to isolate serum. IgE levels were determined by immunoassay using 96-well ELISA plates (Costar). Plates were coated with IgE capture Ab (clone R35-72; BD Pharmingen), blocked with 1% BSA/PBS, and then incubated with IgE standard (BD Pharmingen) or serum followed by biotinylated rat anti-mouse IgE (clone R35-118; BD Pharmingen). Detection was carried out using streptavidin-HRP (BD Pharmingen) and hydrogen peroxide/2-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid). Absorbance at 405 nm was measured.

Statistical analysis

Statistical analysis was performed using Prism 4 (GraphPad). Comparisons of the mean were made by F test, Student t test, or ANOVA followed by the Tukey-Kramer honestly significant difference post hoc test as necessary. Data are shown as mean ± SEM. Differences with p < 0.05 were considered statistically significant.
Results
Allergic asthma in the COX-1 and COX-2–deficient mice

We first verified, using congenic mouse lines, the contribution of prostanoids to allergic lung disease induced by sensitization and challenge with OVA Ag. COX-1−/− B6 congenic mice were generated by >10 crosses between mice carrying a null allele at this locus and commercially purchased B6 mice. COX-2 mice survive poorly on most inbred genetic backgrounds, in part due to a patent ductus arteriosus (39, 40), and thus, most experiments assessing COX-2 function have used F2 mice, mice expected to carry a random assortment of 129- and B6-derived alleles. To circumvent this problem, we generated two lines of COX-2 mutant mice, the first line on the coisogenic 129 genetic background and the second congenic line on the B6 genetic background. The 129 COX-2−/− females were intercrossed with B6+/+ males to generate congenic F1 progeny. The COX-2−/− and COX-2+/+ littermates were used in the experiments presented in this study. Allergic airway disease was induced through sensitization by an i.p. injection of OVA emulsified in alum and challenged with repeated aerosols of Ag. Inflammation was assessed 24 h after the final Ag challenge.

As expected, our immunization protocol induced a robust cellular influx in B6 WT mice (COX-1+/+) compared with saline-treated animals (Fig. 1A). The F1 OVA-treated controls (COX-2+/+) displayed a similar pattern of increased cellularity. Surprisingly, the loss of either COX-1 or COX-2 had comparable impacts on recruitment of cells into the airways: in each line, the total number of cells recovered by BALF was about twice that observed in the genetically matched controls. The cellular infiltrate present in the airways following Ag challenge was marked by heightened levels of eosinophils, typical of Th2-type allergic responses (Fig. 1B). Characteristic of this type of response, IL-13 levels were elevated in the BALF of WT mice with allergic lung disease compared with saline controls (Fig. 1C). Loss of either COX-1 or COX-2 led to increased levels of this cytokine in the airways. Again, the magnitude of this increase, relative to the WT control, was surprisingly similar in the two lines. Elevated IgE levels were observed in both B6 COX-1−/− and B6/129 F1 COX-2−/− WT
animals (Fig. 1D). However, unlike inflammatory disease in the lung, the loss of neither the COX-1 nor the COX-2 pathway significantly altered levels of this Ig isotype.

AHR following challenge with Mch, a potent airway constrictor, was quantified in intubated mice using a computer-controlled small-animal ventilator. This method allows for measurement of resistance in the central airway and tissue damping. We failed to observe AHR in response to Mch in mice with allergic lung disease. This was also true of the B6/129 F1 mice. Even in the COX-1 and COX-2 mice, which showed elevated levels of inflammation, no difference was observed in the response to methacholine in either parameter (Supplemental Fig. 1A, 1B).

**Contribution of mPGES1 to PGE2 production in the naive and inflamed lung**

The ability to catalyze the conversion of PGH2 to PGE2 has been shown in vivo alteration of PGE2 levels only in the mPGES1 mice (29, 43). We therefore first determined whether mPGES1 mice (29, 43). We therefore first determined whether PGE2 production could be detected in the mPGES1 mice (29, 43), as described above. Lungs were harvested and the levels of PGE2 were determined by enzyme immunoassay (Fig. 2). PGE2 production could be detected in the lungs collected from mice sensitized and challenged with OVA, even in the COX-1– and COX-2–deficient animals. This increase was entirely dependent on expression of the mPGES1 synthase, indicating that animals lacking this synthase provide an appropriate model for determining whether loss of this COX1/2 downstream pathway contributes to the increased disease observed in the COX-1– and COX-2–deficient mice.

**Impact of PGE2 on allergic lung inflammation**

PGE2 levels in the lungs increase dramatically after allergic lung disease, and this increase is absent in both the COX-1– and COX-2–deficient mice (Supplemental Fig. 2), supporting the hypothesis that loss of this prostanoïd could contribute to the increased disease observed in both of these mouse lines. To test this hypothesis, mice lacking mPGES1, and their congenic controls, were sensitized and challenged, as previously described. Twenty-four hours after the final challenge, the impact of mPGES1 synthase on inflammation of the airways, IgE production, and airway mechanics was assessed. Surprisingly, and contrary to our prediction based on analysis with the COX-1–/COX-2–deficient mice, mice lacking mPGES1 had significantly less cellular infiltrate and associated eosinophilia in comparison with OVA-challenged WT animals (Fig. 3A, 3B). A significant decrease in IL-13 production was observed in the BALF of the mPGES1−/− mice compared with WT control animals (Fig. 3C). No difference in serum IgE levels was observed between mPGES1−/− mice and their genetic controls (Fig. 3D). IL-4 production is critical for IgE isotype switching (44); therefore, we characterized IL-4 concentrations present in lung homogenate following induction of allergy in this model (Fig. 3E). No difference was observed in the production of this Th2 cytokine between the inflamed lungs of WT and mPGES1−/− mice. To study this further, an additional experiment was carried out to examine proliferation and cytokine production by splenocytes from immunized and challenged mice. The proliferative response of the mPGES1−/− cells to Ag did not differ significantly from that of control cultures, nor was a significant difference observed in the production of IFN-γ or IL-17a. Similar to the BALF, a decrease in IL-13 levels was observed in these cultures, although in this case, the decreased production by mPGES1−/− cells did not achieve statistical significance (Supplemental Fig. 3).

Changes in airway mechanics were determined, as previously described. As was the case for the COX-1– and COX-2–deficient cohorts, inflammation and allergic airway disease induced using this immunization protocol did not result in AHR in any parameter, either in the WT animals or in the mPGES1−/− line (Supplemental Fig. 1C).

**Effect of PGE2 on lung inflammation in mice carrying a transgenic OVA-specific TCR**

The observation that IL-4 and IgE concentrations were unaffected by endogenous levels of PGE2 suggests that proinflammatory actions mediated by this prostanoïd occur subsequent to the sensitization phase of Ag. To explore this, we examined the induction of IgE and the response of splenocytes to Ag in sensitized animals prior to challenge with aerosolized Ag (Supplemental Fig. 3). No difference was observed in serum IgE between WT and mPGES1−/− deficient mice. Splenocytes isolated from WT and mPGES1−/− animals a week after booster sensitization demonstrate similar proliferative responses, and no difference was observed in the production of IL-13, IFN-γ, or IL-17a between groups. Collectively, these results indicate that the reduced inflammation observed in the mPGES1−/− lungs is unlikely to reflect alterations in the sensitization of mice to Ag, but rather the response of exposure of the lungs in sensitized animals to Ag.

To explore this further, we determined whether loss of mPGES1 would alter the development of lung inflammation in OT-II mice. These mice carry a transgenic TCR specific to OVA (45), and thus, exposure of the airways to this Ag results in inflammation in non-sensitized animals. In this case, however, the prominent cell type in the BALF is the neutrophil, and thus, this response is thought to model nonatopic allergic lung disease (46). Mice lacking mPGES1 were crossed to congenic B6 mice carrying the OT-II transgene. As expected, mice lacking the transgene OT-II (−), showed little inflammation in response to OVA challenge. In contrast, robust cell recruitment was observed in transgenic WT mice (Fig. 4A). Transgenic mPGES1−/− animals showed a significant attenuation in

![FIGURE 2](http://www.jimmunol.org/)
cell infiltration compared with WT controls. This attenuation reflects significantly fewer granulocytes present in the BALF of WT animals. Although increased numbers of cells are also observed in BALF collected from mPGES1−/− animals, the total cell count was significantly reduced compared with similarly treated WT control animals (*p < 0.001). The decrease in the cellularity of the BALF of the mPGES1−/− mice correlates with a significant decrease in the number of eosinophils in the BALF of these animals compared with the numbers present in the BALF from the control animals (*p < 0.001). IL-13 levels in the BALF collected from OVA-sensitized and -challenged animals are significantly higher than those measure in saline-treated cohorts, both WT and mPGES−/− animals; however, higher levels are observed in the samples collected from OVA-treated WT animals relative to levels in BALF from mPGES1−/− animals (*p < 0.05). OVA sensitization and challenge results in an increase in total serum IgE of a similar magnitude in WT and mPGES1−/− animals. IL-4 levels in whole-lung homogenates do not differ significantly between samples prepared from mPGES1−/− mice and controls. As expected, both groups showed levels elevated in comparison with samples prepared from saline treated cohorts. Experiments for (A)–(D) were conducted three times independently, and data from one experiment are shown. Data for (E) was generated once. For (A)–(D): mPGES1+/+ saline, n = 4; −/− saline, n = 3; +/− OVA, n = 10; −/− OVA, n = 11; for (E): mPGES1+/+ saline, n = 2; −/− saline, n = 3; +/− OVA, n = 5; −/− OVA, n = 5.

**Individual contributions of lung and recruited inflammatory cells to PGE2-mediated allergic responses**

As shown above, mPGES1 contributes to the PGE2 present in the healthy lung. To determine the relative contributions of mPGES1 produced by the lung and that produced by the recruited immune cells to this model of allergic lung disease, we studied the development of allergy in bone marrow chimeras. We first established that the contribution of mPGES1 to the allergic response was not altered in animals undergoing this experimental procedure. The difference in the OVA-induced cellularity of the BALF between WT mice irradiated and reconstituted with WT marrow (WT→WT) compared with that observed in mPGES1−/− irradiated and reconstituted with autologous marrow (knockout [KO]→KO) recapitulated the differences observed between these groups in previous experiments (Figs. 5 compared with 3A).

We next asked whether PGE2 produced by the immune cells recruited to the lung during allergic inflammation contributes to allergic airway disease. To address this, WT mice were irradiated and reconstituted with either WT (WT→WT) or mPGES1−/− (KO→WT) bone marrow. Reconstitution of mice with mPGES1−/−...
have attenuated allergy compared with animals in which all cells are capable of producing PGE2 (WT→WT). Lung inflammation was attenuated in OVA-sensitized and challenged WT→KO animals compared with animals in which both the lung and the bone marrow express mPGES1 (WT→WT). A significant decrease in BALF cellularity was observed, again primarily reflecting reduced recruitment of eosinophils (Fig. 7A, 7B). IL-13 production was also reduced in this group (Fig. 7C). These observations suggest that mPGES1 produced by cells in the lung, not recruited leukocytes, contributed to the development of allergic disease in response to OVA. Consistent with the studies reported above, IgE levels were not significantly affected by loss of lung mPGES1 (Fig. 7D).

**Discussion**

Previous studies have shown that in the absence of COX-1 or COX-2, Ag exposure results in more severe allergic lung disease (23). Using mice lacking mPGES1 synthase, we show that attenuation of PGE2 synthesis in the COX-1– and COX-2–deficient mouse does not account for the increase in disease observed in these mouse lines. In fact, in this model, mPGES1-deficient mice showed reduced airway inflammation, indicating that PGE2 enhances this aspect of allergic disease.

The impact of the genetic composition of mouse lines on the development of various aspects of allergic lung disease has been well established (47–50). The majority of the early studies assigning roles for COX-1 and COX-2 metabolites in inflammatory responses were carried out using mice of mixed genetic background, thus the representation of B6 and 129 genes in the COX-deficient and control animals can be very different. We therefore first verified that the protection that COX-1 and COX-2 provided in this response could be observed when congenic animals were studied. Consistent with previous work, we report that both COX-1– and COX-2–dependent PGs limit allergic inflammation in the lung. However, we show that both enzymes provided the mice with a similar level of protection. This differs from previous studies in which loss of COX-1 was reported to have a greater role than COX-2 both in production of PGE2 in the naive and inflamed lung as well as in limiting allergic inflammation (23). Because COX-1 and COX-2 have unique but overlapping patterns of expression and, depending on the cell type, can lead to the preferential production of a particular eicosanoid, this observation suggests that multiple PGs or PGEs made by different cells types limit inflammation in this model.

We saw no development of AHR in either the COX-1– or COX-2–deficient animals. This is not surprising given the genetic background of the mice. AHR is often absent in B6 mice (47, 48, 50). In previous studies, inflammation associated with loss of COX-1 was reported to have a similar level of protection. This differs from previous studies in which loss of COX-1 was reported to have a greater role than COX-2 both in production of PGE2 in the naive and inflamed lung as well as in limiting allergic inflammation (23). Because COX-1 and COX-2 have unique but overlapping patterns of expression and, depending on the cell type, can lead to the preferential production of a particular eicosanoid, this observation suggests that multiple PGs or PGEs made by different cells types limit inflammation in this model.

Early work suggested that PGE2 could play an important role in regulating the differentiation of mouse B lymphocytes to IgE-secreting cells (52). However, this role was not supported by the report that IgE levels were actually higher in the COX-1 and COX-2 Ag-treated animals (23). Our study did not observe this increase in the COX-1– and COX-2–deficient animals compared with their genetically matched controls and therefore does not support a role for PGE2 in switching B cells to IgE production. No
difference was noted in serum IgE levels among COX-1−/−, COX-2−/−, or mPGES1−/− and their control animals after induction of a Th2 response. However, direct comparison of the IgE response of COX-deficient animals reported in this study and those reported previously is difficult for a number of reasons. Not only do our studies use congenic mice, but also the cohort examined in this study was between 8 and 12 wk of age, whereas previous studies examined mice that ranged in age from 5–9 mo. In addition, these studies evaluated IgE levels in the BALF, whereas we examined serum IgE.

In patients with allergic asthma, inhaled PGE2 is reported to attenuate both the early- and late-phase response after exposure to Ag (12, 13, 15, 16). PGE2 has also been shown to limit inflammation in animal models of asthma (14, 17, 53). Given this, it seemed likely that the heightened inflammation observed in the COX-deficient mice reflected a loss of this protective prostanoid. Indeed, induction of allergic disease with OVA dramatically increased PGE2 levels in the lung, and this augmentation was not observed when COX-1, COX-2, or mPGES1 was absent, suggesting that both enzymes are capable of coupling with mPGES1.

**FIGURE 6.** Contribution of PGE2 from bone marrow-derived cell populations to OVA-induced lung inflammation. Lethally irradiated WT mice were reconstituted with either WT bone marrow (WT→WT) or mPGES1−/− bone marrow (KO→WT). (A) As expected, an increase in the cellularity of the BALF was observed in samples collected from the animals sensitized and challenged with OVA. No significant difference was measured in the total number of cells present in the BALF of the two groups (WT→WT versus KO→WT). (B) Morphological analysis of cell types present in BALF revealed elevated levels of eosinophils in both OVA-treated groups, and again, the numbers of these cells did not differ significantly between the animals that had received the WT versus the mPGES1−/− marrow. (C) No difference is observed in the level of IL-13 in the BALF of the two OVA-treated groups. (D) Total serum IgE concentrations are elevated to a similar degree in groups sensitized and challenged with OVA. This experiment was carried out twice, and data from one trial are shown. For WT→WT: saline, n = 3; OVA, n = 8; KO→WT: saline, n = 2; OVA, n = 8.

**FIGURE 7.** Contribution of PGE2 produced by radiation-resistant lung populations to allergic inflammation. WT mice or mPGES1−/− mice exposed to lethal doses of radiation were reconstituted with WT bone marrow, (WT→WT) and (WT→KO), respectively. BALF was collected from OVA-sensitized and -challenged animals, and total cell numbers (A) and cell differentials (B) were determined. A decrease in both the total cell count and the number of eosinophils in the BALF was observed in samples from mPGES1−/− mice reconstituted with WT marrow compared with samples from similarly reconstituted and treated WT animals (WT→WT). *p < 0.01. (C) IL-13 levels are significantly higher in the BALF from OVA-sensitized and -challenged WT→WT mice compared with levels in BALF from similarly treated mPGES1−/− animals that received WT bone marrow (WT→KO). *p < 0.05. (D) Total serum IgE concentrations were elevated to similar levels following OVA sensitization and challenge in both WT→WT and WT→KO animals. This experiment was conducted twice, and data from one trial are shown. For WT→WT: saline, n = 4; OVA, n = 8; WT→KO: saline, n = 4; OVA, n = 7.
to promote prostancoid production during lung inflammation. However, unlike a genetic loss of COX enzymatic activity, a loss of mPGES1 did not result in heightened disease—in fact, quite the opposite; loss of this pathway attenuated the inflammatory response. Our results are consistent with a model in which the primary protective COX-dependent eicosanoid is prostacyclin, not PGE2. Mice lacking the I-prostanoid receptor, specific for prostacyclin, were reported to have more severe allergic inflammation in the lung (54). Prostacyclin, but not PGE2, was also shown to protect against the development of fibrosis in the bleomycin model of idiopathic pulmonary fibrosis (55), suggesting that, at least in the rodent lung, this might be the most important anti-inflammatory prostancoid.

We cannot rule out the possibility that the lack of a protective role for PGE2 in this study is specific to this particular model and immunization protocol. A recent study examining the function of mPGES1 in a house dust mite Ag (Der f)-induced allergic model reported that PGE2 limited vascular changes associated with chronic exposure to Ag, whereas decreased PGE2 had no significant impact on total recruitment of inflammatory cells to the lungs after Der f challenge (56). However, the vascular remodeling that this study showed was enhanced in the mPGES1−/− mice is associated with chronic models of asthma and is not apparent in the acute model used in our study, preventing extension of this finding to this model of allergic lung disease. In contrast to our findings, decreased PGE2 had no significant impact on recruitment of inflammatory cells to the lungs after Der f challenge. Again, this difference might reflect different roles for PGE2 in an acute allergic response, such as that induced by OVA and adjuvant versus a chronic model established by inhalation of a complex Ag with intrinsic ability to activate the innate immune response. Alternatively, it could reflect the fact that the mPGES1−/− animals were compared with purchased WT B6 mice, whereas both the mPGES1−/− and WT mice used in our studies were bred in the same facility, as studies have highlighted the importance of environmental factors, including the microbiome, in modulating the immune response (57–60), and it is possible that some phenotypes reflect such differences in addition to the genetic lesion under study.

Both our findings and the phenotype of mPGES1−/− animals in the Der f allergic model do not support early reports of heightened inflammation in EP2−/− mice sensitized and challenged with OVA (26). The reason for this discrepancy is not apparent; however, we have been unable to reproduce this finding using B6 congenic EP2−/− mice (M. Nguyen and B.H. Koller, unpublished observations). Furthermore, previous work in our laboratory has indicated that PGE2, through the EP3 receptor, can promote inflammation by augmenting IgE-mediated mast cell degranulation, and, in some circumstances, PGE2 alone is sufficient to mediate this response in rodents (61, 62).

Much of the support for the hypothesis that PGE2 plays a protective role in the lung, limiting inflammation, comes from studies in which exposure of mice to Ag is accompanied by inhalation of PGE2, its stable analog, or a PGE2 receptor preferring antagonist and agonist (17, 53, 63). In vitro studies have reinforced this hypothesis, with studies such as those which have shown PGE2 to be effective in limiting migration of eosinophils and increasing production of IL-10 by dendritic cells and naive T cells (22, 63, 64). However, extrapolating findings from either or both of these types of studies to develop models that predict the contribution of PGE2 to inflammatory responses in vivo has proven difficult. Some of this difficulty is related to the fact that very few of the pathways attributed to PGE2 through pharmacological studies with inhaled PGE2 or PGE2 receptor preferring agonists/antagonists are supported by evaluation of mice lacking specific PGE2 receptors or a combination of receptors. In some cases, the discrepancies may reflect the effective dose and specificity of the reagents used. For example, early studies assigning anticoagulatory properties to PGE2 were later shown to reflect the ability of PGE2 at concentrations used in these studies to activate the prostacyclin receptor (65). Thus, it is possible that some of the protective actions of inhaled PGE2 and EP receptor agonist are incorrectly assigned to the PGE2 pathway. Carrying out these experiments in mice lacking the I-prostanoid receptor and or EP receptors should resolve many of these issues. In some cases, inconsistency among results obtained using the various approaches might simply reflect the fact that loss of a PGE2 receptor may have far less consequence for the organism than stimulation of the same pathway due to compensatory pathways active in vivo. For example, stimulation of naive T cells with PGE2 in vitro can inhibit production of a proinflammatory cytokines, such as IFN-γ (64), but in vivo, the absence of PGE2 does not necessarily lead to altered expression of this cytokine following stimulation (56), emphasizing the point that many other inflammatory mediators, distinct from PGE2, can activate the same downstream pathways to upregulate responses. Inhaled PGE2 through the EP2 receptor limits airway constriction to methacholine (11). However, in mice with inflamed airways, the dose-response curve is not shifted to the left in mice lacking EP2 (J.M. Hartney and B.H. Koller, unpublished observations), suggesting that in the inflamed airway, other pathways available are capable of regulating airway tone.

Not only were we unable to assign a protective role to PGE2, but also our studies indicate a novel role for PGE2: in some allergic responses, PGE2 acts as a proinflammatory mediator, enhancing inflammation in the lung. To further define this proinflammatory action of PGE2, we generated bone marrow chimeras, animals in which either the lung or the recruited immune cells were deficient in the enzyme. The results from studies with these animals indicated that PGE2 produced by the lung, rather than from the recruited immune cells, contributed to the inflammatory response. Furthermore, PGE2 does not alter the development of Ag-specific T and B cell populations, but rather plays a role either in the expansion of these populations after challenge or in the recruitment of the cells to the lung. This interpretation was supported by study of mPGES1-deficient animals carrying an OVA-specific transgene. Loss of PGE2 synthesis limited the development of inflammation when these animals were challenged with Ag, implicating PGE2 in the effector phase of this response in the lung. The lack of a role for PGE2 in the sensitizing phase of the allergic response correlates well with the studies of these mice in the Der f allergic model (56). No difference was observed in the repertoire of T cells elicited by this Ag.

We cannot yet identify precise mechanisms by which PGE2 contributes to the inflammatory response in the lung. As discussed above, PGE2 can augment mast cell degranulation in vitro and in vivo, and this action is mediated through the EP3 receptor (61, 62), suggesting that perhaps PGE2 augments inflammation by increasing the release of mediators from these cells. However, the immunization protocol used in this study is not mast cell dependent (66), making it unlikely that this effector cell contributes substantially to the inflammatory response. PGE2 can also increase vascular permeability and thus increase vascular leakage and formation of inflammatory exudates (67). For example, instillation of PGE2 was reported to increase migration of neutrophils into airways in response to complement exposure (68). This response was attributed to vascular changes, as it was attenuated by treatment with a vasoconstrictor. PGE2 has been reported to influence
many aspects of epithelial cell physiology, including chemokine and cytokine profiles, release of mucins, ion transport, and ciliary beat (69–73). For instance, PGE2 can stimulate the release of IL-6 from many cell types (61, 69, 74, 75) and IL-6 can contribute to inflammation in some allergic models (75, 76). Additional experiments will be required to define precisely the circumstances and the mechanism by which inhibition of PGE2 limits disease in this allergic lung.

In summary, our studies show that loss of mPGES1, the primary enzyme required for production of PGE2 from COX-1 and COX-2 metabolites, is not required for Th2 polarization following sensitization of mice to OVA. However, although PGE2 has largely been considered protective, playing a role in limiting inflammation of mice to OVA. However, although PGE2 has largely

References

The authors have no financial conflicts of interest.

Acknowledgments

We thank Dr. Coy Allen for assistance with airway response data, Rebecca Parris for genotyping, and Ben Buck for assistance with statistical analysis.

Disclosures

The authors have no financial conflicts of interest.